论文部分内容阅读
目的:探讨米非司酮联合孕三烯酮在预防子宫内膜异位症术后复发中的临床疗效。方法:选取我院于2010年4月到2011年8月收治的98例子宫内膜异位症术后患者,将98例子宫异位症术后患者随机分为治疗组与对照组,其中治疗组异位症术后患者采用米非司酮联合孕三烯酮进行药物预防,而对照组患者仅采用孕三烯酮进行术后预防治疗,着重观察两组患者的预防复发情况、临床病症变化、体征指标、药物副作用、盆腔超声波检查结果、患者接受情况等,就两组的临床用药预防效果进行了统计分析。结果:米非司酮与孕三烯酮两种药物均能起到术后复发预防功用,但是米非司酮联合孕三烯酮进行子宫内膜异位症术后复发预防比单纯应用孕三烯酮进行术后复发预防效果更加明显,且临床不良反应较少,两组对比差异明显(P<0.05),有统计学意义。结论:米非司酮联合孕三烯酮用于子宫内膜异位术后复发预防治疗具有较高的应用价值,可以推广应用。
Objective: To investigate the clinical efficacy of mifepristone combined with gestrinone in the prevention of postoperative recurrence of endometriosis. Methods: A total of 98 patients with endometriosis who were treated in our hospital from April 2010 to August 2011 were enrolled. 98 patients with uterine atresia were randomly divided into treatment group and control group, in which treatment Group patients with postoperative ectopic patients with gestrinone combined with gestrinone for drug prevention, while patients in the control group were treated with gestrinone for postoperative prophylaxis, focusing on the two groups of patients with prevention and treatment of recurrence, changes in clinical conditions , Signs, drug side effects, pelvic ultrasound findings, patient acceptance, etc., on the clinical efficacy of the two groups were statistically analyzed. Results: Both mifepristone and gestrinone could play a role in postoperative recurrence prevention. However, the relapse prevention of endometriosis with mifepristone and gestrinone was better than that of pregnancy alone Enkephalin for postoperative recurrence prevention effect is more obvious, and the clinical adverse reaction is less, the difference between the two groups was significant (P <0.05), with statistical significance. Conclusion: The use of mifepristone combined with gestrinone in the prevention and treatment of post-endometriosis recurrence has a high value and can be widely applied.